ABBVIE, INC. for ABBVIE INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Draft legislation relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| STEPHEN SCANGO | — |
Copyright/Patent/Trademark CPT
Patent litigation reform issues and issues related to post-grant proceedings at the PTO Value of intellectual property
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| BINTA BEARD | — |
| STEPHEN SCANGO | — |
Health Issues HCR
H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 H.R.7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage. 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| BINTA BEARD | — |
| STEPHEN SCANGO | — |
Medicare/Medicaid MMM
H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13938, White House Executive Order on Increasing Drug Importation to Lower Prices for American Patients Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| BINTA BEARD | — |
| STEPHEN SCANGO | — |
Trade (domestic/foreign) TRD
USMCA and related policy issues Policy proposals impacting biopharmaceutical supply chain
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| STEPHEN SCANGO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.